Redcare Pharmacy delivers strong Q3, with revenue increasing 18% driven by Rx and adjusted EBITDA margin up 1.0pp YoY to 3.4%.

Group revenue increased 18% year over year to EUR 847 million; nine-month revenue reached EUR 2.55 billion, up 19% year over year. Non-Rx revenue grew 9%, while Rx revenue increased 31%, with Rx Germany maintaining its strong momentum at 56% growth. Adjusted EBITDA increased 68% year over year to EUR 28.7 million in Q3 with margin up 1.0pp to 3.4%. The active customer base increased by 0.5 million during Q3 to 15.2 million. Sevenum, the Netherlands, October 29, 2026. Redcare Pharmacy delivered another strong performance in the third quarter of 2026, realizing a net profit for the second consecutive quarter. Group revenue increased 18% to EUR 847 million (Q3'25: EUR 719 million) driven by strong Rx growth in Germany. Adjusted EBITDA increased 68% to EUR 29 million, corresponding to a margin of 3.4% versus 2.4% in Q3 2025. For the first nine months of 2026, Group revenue increased 19% to EUR 2.55 billion (9M'25: EUR 2.15 billion) while adjusted EBITDA reached EUR 73 million, a margin of 2.9%. The active customer base reached 15.2 million at the end of September, an increase of 1.5 million or 11% year over year and 0.5 million versus Q2. Customer satisfaction remained high with an overall Net Promoter Score (NPS) of 76 and an e-Rx NPS of 78. Peter Schmid von Linstow, CEO of Redcare Pharmacy, comments: „Our Rx business in Germany has performed strongly in Q3 and we are especially happy about having increased our active customer base by 123K customers in Q3, nearly doubling the 65K increase in Q2. Q3 was also a significant step forward in terms of profitability in DACH where we increased EBITDA margin by 1.2pp year over year to 4.2%. We will continue to optimize our marketing mix and increase operational leverage to translate scale into profitability across all segments.” Strong growth in Rx and robust growth in non-Rx. Group non-Rx revenue increased 9% year over year to EUR 489 million (Q3'25: EUR 447 million). In DACH, non-Rx revenue grew 8% to EUR 340 million, compared to EUR 315 million in Q3 2025. Rx revenue increased 31% to EUR 358 million (Q3'25: EUR 272 million) driven by Germany where Rx revenue grew 56% to EUR 197 million. In Switzerland (MediService), Rx revenue grew 10% to EUR 161 million. Total DACH revenue increased 19% to EUR 697 million (Q3'25: EUR 587 million) while total International revenue grew 13% to EUR 149 million (Q3'25: EUR 132 million). Significant improvement of profitability. Gross profit increased to EUR 185 million in Q3'26 (Q3'25: EUR 159 million). The gross profit margin was 21.8%, compared with 22.1% in Q3'25. The year-over-year decline of 0.3pp was considerably smaller than the 1.7pp point decline in Q2. Adjusted selling and distribution expenses, which amounted to EUR 132 million, accounted for 16% of revenue, improving from 17% in Q3’25. This reduction is driven by lower marketing spend and lower cost per order. Adjusted administrative expenses, which totaled EUR 24 million, accounted for 3% of revenue, in line with Q3’25. As a result, the adjusted EBITDA increased 68% to EUR 29 million, compared to EUR 17 million in the prior-year quarter. The adjusted EBITDA margin improved by 1.0pp to 3.4%. For the first nine months of 2026, Group adjusted EBITDA reached EUR 73 million, a margin of 2.9%. In Q3, net income was positive at EUR 1 million and free cash flow was EUR 15 million. DACH contributed an adjusted EBITDA of EUR 29 million, up from EUR 18 million in Q3'25, with a margin of 4.2% after 3.0% last year. The International segment's adjusted EBITDA was flat year over year at EUR -1 million, corresponding to a margin of -0.4%. Full-year 2026 guidance. Redcare Pharmacy confirms its upgraded guidance for the full year 2026: Total revenue growth of 16% to 18%. Non-Rx growth of 10% to 12%. Rx revenue in Germany between EUR 730 and 760 million, representing growth of 45% to 51%. Adjusted EBITDA margin between 2.5% and 3.0%. ___
Revenue breakdown.

EUR million	Q3 2025	Q3 2026	Growth	9M 2025	9M 2026	Growth
Consolidated net revenues	719	847	18%	2,146	2,550	19%
DACH
Rx revenues	272	358	31%	758	1,013	34%
Thereof Germany	126	197	56%	348	544	57%
Thereof Switzerland (MediService)	146	161	10%	410	469	14%
Non-Rx revenues	315	340	8%	986	1,074	9%
International
Non-Rx revenues	132	149	13%	402	463	15%

Profitability.

EUR million	Q3 2025	Q3 2026	9M 2025	9M 2026
Consolidated EBITDA	15	28	39	70
Consolidated adjusted EBITDA	17	29	44	73
Adjusted EBITDA margin	2.4%	3.4%	2.1%	2.9%
DACH EBITDA	16	29	45	74
DACH adjusted EBITDA	18	29	48	75
Adjusted EBITDA margin	3.0%	4.2%	2.8%	3.6%
International EBITDA	(1)	(1)	(6)	(4)
International adjusted EBITDA	(1)	(1)	(4)	(3)
Adjusted EBITDA margin	(0.4)%	(0.4)%	(0.9)%	(0.6)%

___
Upcoming publications and events.

Date		Publication / Event
January 11, 2027		FY 2026 Trading Update
March 03, 2027	FY 2026 Financial Results